Acyclic nucleoside phosphonates in the chemotherapy of DNA virus and retrovirus infections

Intervirology

Volumn 40, Issue 5-6, 1997, Pages 295-303

  De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Acyclic nucleoside phosphonates; HPMPC (cidofovir); PMEA (adefovir); PMPA

Indexed keywords

ACYCLIC NUCLEOSIDE; ADEFOVIR; CIDOFOVIR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CHEMOTHERAPY; CYTOMEGALOVIRUS; DNA VIRUS; FELINE IMMUNODEFICIENCY VIRUS; HEPATITIS B VIRUS; HERPES VIRUS; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; NONHUMAN; PAPILLOMA VIRUS; POLYOMA VIRUS; POXVIRUS; PRIORITY JOURNAL; RETROVIRUS; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; VIRUS TYPING;

ADENINE; ANIMALS; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CYTOSINE; DNA VIRUS INFECTIONS; HUMANS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; RETROVIRIDAE INFECTIONS;

EID: 2642651109     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000150563     Document Type: Article

References (66)

1. De Clereq E: T rends in the development of new antiviral agents for the chemotherapy of infections caused by herpesviruses and retroviruses, Rev Med Virol 1995;5:149-164.
2. Field AK, Biron KK: ‘The end of innocence’ revisited: Resistance of herpesviruses to antiviral drugs, Clin Microbiol Rev 1994;7:1-13.
3. De Clercq E: Broad-spectrum anli-DNA virus and anti-retrovirus activity of phosphonvlmc-thoxyalkylpurines and -pyrimidines, Biochem Pharmacol 1991;42:963-972.
4. Cihlar T, Chen MS: Identification of enzymes catalyzing two-step phosphorylation of cidofo-vir and the effect of cytomegalovirus infection on their activities in host cells, Mol Pharmacol 1996:50:1502-1510.
5. Balzarini J, Nave J-F, Becker MA, Tatibana M, De Clercq E: Kinetic properties of adenine nucleotide analogues against purified 5-phos-phoribosyl-1-pyrophosphate synthetase from £, coli, rat liver and human erythrocytes, Nucleosides Nuclcotides 1995; 14: 1861-1871.
6. Merta A, Votruba I, Jindrich J, Holy A, Cihlar T, Rosenberg I, Otmar M, Herve TY: Phosphorylation of 9-(2-phosphonomcthoxyethyl)-adenine by AMP(dAMP) kinase from L1210. Biochem Pharmacol 1992:44:2067-2077.
7. Snoeck R, Sakuma T, De Clercq E, Rosenberg I, Holy A: 6S>l(3-hydroxy-2-phosphonylmc-thoxyprophylR'ytosine, a potent and selective inhibitor of human cytomegalovirus replication, Antimicrob Agents Chemothcr 1988:32: 1839-1844.
8. Nevts J, Snoeck R, Schols D, Balzarini J, De Clercq E: Selective inhibition of human cytomegalovirus DNA synthesis by 3-hv-droxy - 2 - phosphonylmethoxypropyl) cytosine [ffil-HPMPC] and 9-(1.3-dihydroxv-2-propox-ymethyljguanine (DHPG), Virology 1990:179: 41-50.
9. Neyts J, Snoeck R, Balzarini J, De Clercq E: Particular characteristics of the anti-human cytomegalovirus activity of 6S7-1-(3-hvdroxy-2-phosphonylmcthoxypropv!)cytosinc (HPMPC) in vitro, Antiviral Res 1991;16:41-52.
10. Connelly MC, Robbins BL, Fridland A: Mechanism of uptake of the phosphonate analog (S)-l-(3-hydroxy-2-phosphonylmethoxypropvl)cy-tosine (HPMPC) in Vero cells, Biochem Pharmacol 1993;46:1053-1057.
11. Ho H-T, Woods KL, Bronson JJ, De Boeck H, Martin JC, Hitchcock MJM: Intracellular metabolism of the anliherpes agent i, S>l-[3-hy-droxy-2-(phosphonylmethoxy)propyl]cytosinc, Mol Pharmacol 1992;41:197-202.
12. Cihlar T, Votruba I, Horska K, Liboska R, Rosenberg I, Holy A: Metabolism of l-CSJ-(3-hydroxy-2-phosphonylmcthoxypropyl)cyto-sine (HPMPC) in human embryonic lung cells, Collect Czech Chem Commun 1992:57:661-672.
13. Nacsens L, Snoeck R, Andrei G, Balzarini J, Neyts J, De Clercq E: HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: A review of their pharmacology and clinical potential in the treatment of viral infections, Antiviral Chem Chemother 1997;8:1-23.
14. Kramata P, Votruba I, Otova B, Holy A: Different inhibitory potencies of acyclic phos-phonomethoxyalkyl nucleotide analogs toward DNA polymerases a, X and s, Mol Pharmacol 1996:49:1005-1011.
15. Cihlar T, Chen MS: Incorporation of selected nucleoside phosphonales and anti-human immunodeficiency virus nucleotide analogues into DNA by human DNA polymerases u, 3 and y, Antiviral Chem Chemothcr 1997:8:187-195.
16. Xiong X, Smith JL, Chen MS: Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation, Antimicrob Agents Chemother 1997: 41:594-599.
17. De Clcrcq E: Therapeutic potential of HPMPC as an antiviral drug, Rev Med Virol 1993:3:85-96.
18. De Clercq E: I herapcutic potential of cidofovir (HPMPC, Vistide™) for the treatment of DNA virus (i, e, herpes-, papova-, pox- and adenovirus) infections, Verb K Acad Geneeskd Beig 1996;58:19-49.
19. Neyts J, De Clereq E: In vitro and in vivo inhibition of murine gamma herpes virus 68 replication by selected antiviral agents, Antimicrob Agents Chemother 1998;42:170-172.
20. Kedes DH, Ganern D: Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs, J Clin Invest 1997:99:2082-2086.
21. Meadows KP, Tyring SK, Pavia AT, Rallis TM: Resolution of recalcitrant molluscum con-tagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir, Arch Dermatol 1997;133:987-990.
22. Reymcn D, Naesens I, Balzarini J, Holy A, Dvorakova H, De Clercq E: Antiviral activity of selected acyclic nucleoside analogues against human herpesvirus 6. Antiviral Res 1995:28: 343-357.
23. Takahashi K, Suzuki M, Iwata Y, Shigeta S, Yamanishi K, De Clercq E: Selective activity of various nucleoside and nucleotide analogues against human herpesvirus 6 and 7. Antiviral Chem Chemother 1997;8:24-31.
24. Neyts J, De Clereq E: Antiviral drug susceptibility of human herpes virus type 8. Antimicrob Agents Chemothcr 1997:41:2754-2756.
25. Andrei G, Snoeck R, Vandcputtc M, De Clereq E: Activities of various compounds against murine and primate polyomaviruscs, Antimicrob Agents Chemother 1997;41:587-593.
26. de Oliveira CBR, Stevenson D, LaBree L, McDonnell PJ, Trousdale MD: Evaluation of cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model, Antiviral Res 1996; 31:165-172.
27. De Clercq E, Holy A: Efficacy of fSJ-l-(3-hydroxy-2-phosphonylmethoxypropyl)cyto-sine in various models of herpes simplex virus infection in mice, Antimicrob Agents Chemother 1991:35:701-706.
28. Yang H, Datcma R: Prolonged and potent therapeutic and prophylactic effects of 1-[(3-hydroxy - 2 - phosphonylmelhoxy) propyl] cyto -sine against herpes simplex virus type 2 infections in mice, Antimicrob Agents Chemother 1991;35:1596-1600.
29. Neyts J, Balzarini J, Naesens L, De Clercq E: Efficacy of fS>l-(3-hydro,\y-2-phosphonylme-thoxypropyl)cylosinc and 9-(l,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice, J Med Virol 1992:37:67-71.
30. Neyts J, Sobis H, Snoeck R, Vandeputte M, De Clereq E: Efficacy of (Sj-I-(3-hydroxy-2-phos-phonylmelhoxypropyficylosinc and 9-(1.3-di-hvdroxy-2-propoxymethvl)guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and irnmu-nodeficient mice, Eur J Clin Microbiol Infect Dis 1993;12:269-279.
31. Tsai C-C, Foilis KE, Sabo A, Beck TW, Grant RF, Bischofberger N, Benvenistc RE, Black R: Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmcthoxypropyl)adeninc, Science 1995:270:1197-1199.
32. Van Rompay KKA, Cherrington JM, Marthas ML, Berardi CJ, Mulato AS, Spinner A, Tarara RP, Canfield DR, Telm S, Bischolberger N, Pedersen NC: 9-[2-phosphonomcthoxy)-pro-pyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques, Antimicrob Agents Chemother 1996:40:2586-2591.
33. Tsai C-C, Follis KE, Beck TW, Sabo A, Bi-schofberger N, Dailey PJ: Effects of (R)-9-(2-phosphonylmethoxypropyDadeninc monotherapy on chronic SIV infection in macaques, AIDS Res Hum Retroviruses 1997:13:707-712.
34. Lalezari JP, Stagg RJ, Kuppcrmann BD, Holland ON, Kramer F, Ives DV, Youle M, Robinson MR, Drew WL, Jaffc HS: Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS, Ann Intern Med 1997;126:257-263.
35. Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group: Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: The HPMPC peripheral cytomegalovirus retinitis trial, Ann Intern Med 1997:126: 264-274.
36. Lalezari JP, Drew WL, Glutzer E, James C, Miner D, Flaherty J, Fisher PE, Cundv K, Han-nigan J, Martin JC: GS;-l-[3-hydroxv-2-(phos-phoiiyImethoxy)propyl]cytosine (cidofovir): Results of a phase I/ll study of a novel antiviral nucleotide analogue, J Infect Dis 1995:171: 788-796.
37. Polis MA, Spooner KM, Baird BF, Manische-witz JF, JatTe HS, Fisher PE, Falloon J, Davey RT Jr, Kovacs JA, Walker RE, Whitcup SM, Nusscnblatt RB, Lane HC, Masur H: Anticy-tomegalovirus activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria, An-timicrob Agents Chcmothcr 1995:39:882-886.
38. Lalezari JP, Drew WL, Glutzcr E, Miner D, Safrin S, Owen WF Jr, Davidson JM, Fisher PE, Jaffc HS: Treatment with intravenous (S>-l-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS, J Infect Dis 1994:170:570-572.
39. Snocck R, Andrei G, De Clcrcq E, Gerard M, Clumcck N, Tricot G, Sadzot-Delvaux C: A new topical treatment for resistant herpes simplex infections, N Engl J Med 1993:329:968-969.
40. Lalczari J, Schacker T, Feinberg J, Gathe J, Lee S, Cheung T, Kramer F, Kessler H, Corey L, Drew WL, Boggs J, McGuire B, Jaffe HS, Safrin S: A randomized, double-blinded, placebo-controlled trial of cidofovir gel for the treatment of acyclovir unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS, J Infect Dis 1997;176:892-898.
41. Sacks SL, Sasadeusz JJ, Hughes A, Shafran S, Diaz-Mitoma F, Trottier S, Sibbald G, McGuire BW, Rudy J, Jaffe HS: Cidofovir topical gel single-dose therapy for recurrent genital herpes in the immunocompetent host: Results of a Canadian multicenter, randomized, double-blind, placebo-controlled dose-escalation pilot study, Ninth International Conference on Antiviral Research, Urabandai, Fukishima, May 1996 (late breaker)
42. Kirsch LS, Arevalo JF, De Clcrcq E, Chavez-de-la-Paz E, Munguia D, Garcia R, Freeman WR: Phase 1/11 study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome, Am J Ophthalmol 1995:119: 466-476.
43. Kirsch LS, Arevalo JF, Chavez-de-la-Paz E, Munguia D, De Clereq E, Freeman WR: Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome, Ophthalmology 1995;102:533-542.
44. Banker AS, Arevalo JF, Munguia D, Rahhal FM, Ishimoto B, Berry C, De Clercq E, Ochabski R, Taskintuna I, Freeman WR: Intraocular pressure and aqueous humor dynamics in patients with AIDS treated with intravitreal cidofovir (HPMPC) for cytomegalovirus retinitis, Am J Ophthalmol 1997; 124:168-180.
45. Blick G, Garton T, Hopkins U, LaGravinese L: Successful use of cidofovir in treating AIDS-related cytomegalovirus retinitis, encephalitis, and esophagitis, J Acquir Immun Defic Syndr Hum Rctrovirol 1997;15:84-85.
46. Brosgart C, Roberts T, Safrin S, Marra CM, Colson N, Jaffe HS: Cidofovir (CDV) therapy for progressive multifocal lcukocncephalopa-thy (PML) in two AIDS patients (Pis) (abstract No 1-5), Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 28 September- I October 1997. p 243.
47. Van Cutscm E, Snocck R, Van Ranst M, Fitcn P, Opdenakker G, Gebocs K, Janssens J, Rul-geerts P, Vantrappcn G, De Clercq E: Successful treatment of a squamous papilloma of the hypopharynx-csophagus by local injections of (SJ-l-(3-hydroxy-2-phosphonylmcthoxypro-pvljcytosine, J Med Virol 1995;45:230-235.
48. Snoeck R, Van Ranst M, Andrei G, De Clercq E, De Wit S, Ponein M, Clumeck N: Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue, N Engl J Med 1995:333:943-944.
49. Snoeck R, Arens M, Muller C, Noel JC, De Clercq E, Bossens M: Preliminary results on the activity of cidofovir for the treatment of cervical intracpithelial neoplasia (CIN) grade III (abstract No 108), Tenth International Conference on Antiviral Research, Atlanta, April 1997. Antiviral Res 1997;34:A72.
50. Snoeck R, Wellens W, Deslooverc C, Van Ranst M, De Clercq E, Fccnstra L: Treatment of severe recurrent laryngeal papillomatosis by local injections of (Sj-l-(3-hvdroxy-2-phospho-nylmethoxypropyl)cytosinc (abstract 24), Abstracts Ninth International Conference on Antiviral Research, Urabandai, Fukushima, May 1996. Antiviral Res 1996:30:A25.
51. Snoeck R, Wellens W, Deslooverc C, Van Ranst M, Naescns L, De Clercq E, Fcenstra L: Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [6S> l-(3-hydroxy-2-phosphonylmethoxvpropyl)cy-tosine], J Med Virol 1998:54:219-225.
52. Zabawski EJ, Sands B, Goetz D, Naylor M, Cockerell CJ: Treatment of verruca vulgaris with topical cidofovir (letter), JAMA 1997:278: 1236.
53. Barditch-Crovo P, Toole J, Hendrix CW, Cun-dy KC, Ebeling D, Jaffe HS, Lictman PS: Antihuman immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-piva!oloxymethyl)phospho-nylmcthoxycthyljadenine) in HIV-infected patients, J Infect Dis 1997;176:406-413.
54. Dceks SG, Collier A, Lalezari J, Pavia A, Rodrigue D, Drew WL, Toole J, Jaffc I IS, Mulato AS, Lamy PD, Li W, Chcrrington JM, Hell-mann N, Kahn J: The safety and efficacy of adefovir dipivoxil, a novel anti-HIV therapy, in HIV infected adults, A randomized, doubleblind, placebo controlled trial, J Infect Dis 1997:176:1517-1523.
55. Decks SG, Barditch-Crovo P, Lictman P, Hwang F, Cundy K, Rooney J, Hellmann N, Kahn J: The safety, pharmacokinetics and antiretroviral activity of intravenous PM PA, a novel anti-HIV therapy, in HIV infected adults, A randomized, double-blind, placebo-controlled phase I/I I trial, Anlimicrob Agents Chemother 1998. in press.
56. Arimilli MN, Kim CD, Dougherty J, Mulato A, Oliyai R, Shaw JP, Cundy KC, Bischofberger N: Synthesis, in vitro biological evaluation and oral bioavailability of 9-[2-(phosphonometh-oxy)propyl]adcnine (PMPA) prodrugs, Antiviral Chem Chemother 1997;8:557-564.
57. Shaw J-P, Sucoka CM, Oliyai R, Lee WA, Arimilli MN, Kim CU, Cundy KC: Metabolism and pharmacokinetics of novel oral prodrugs of 9-[7?j-2-(phosphonomethoxy)pro-pyl]adenine(PMPA) in dogs, Pharm Res 1997; 14:1824-1829.
58. De Clercq E: Development of resistance of human immunodeficiency virus (HIV) to anti-HIV agents: How to prevent the problem? Int J Antimicrob Agents 1997:9:21-36.
59. Cherrington JM, Mulato AS, Fuller MD, Chen MS: Novel mutation (K70E) in human immunodeficiency virus type I reverse transcriptase confers decreased susceptibility to 9-[2-(phos-phonomcthoxy)cthyl]adenine in vitro, Antimicrob Agents Chemother 1996:40:2212-2216.
60. Foli A, Sogocio KM, Anderson B, Kavlick M, Savillc MW, Wainberg MA, Gu ZX, Cherrington JM, Mitsuya H, Yarchoan R: In vitro selection and molecular characterization of human immunodeficiency virus type I with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]-adenine (PMEA), Antiviral Res 1996:32:91-98.
61. Cherrington JM: Human cytomegalovirus: Resistance profile of cidofovir, Int Antiviral News 1997;5:91-92.
62. Cherrington JM, Miner R, Hitchcock MJM, Lalczari JP, Drew WL: Susceptibility of human cytomegalovirus to cidofovir is unchanged after limited in vivo exposure to various clinical regimens of drug, J Infect Dis 1996:173:987-992.
63. Smith IL, Cherrington JM, Jilcs RE, Fuller MD, Freeman WR, Spector SA: High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UI,97 and DNA polymerase genes, J Infect Dis 1997; 176:69-77.
64. Mulato AS, Lamy PL, Li W, Miller MD, Cherrington JM: Genotypic characterization of HIV-1 variants isolated from AIDS patients after prolonged therapy with adefovir dipivoxil (bis-POM PMEA) (abstract No I-II4), Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 28 September- I October 1997. p 264.
65. Cherrington JM, Chandok R, Mulato AS, Lamy PD, Mitsuya H, Wainberg M: In vitro-selection and characterization of HIV-1 variants with reduced susceptibility to PMPA (abstract No 1-113), Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 28 September - 1 October 1997. p 264.
66. Xiong X, Flores C, Gibbs C, Toole J: Lack of cross-resistance to PMEA for human hepatitis B DNA polymerases which express lamivudinc resistance codons, Abstracts of the Meeting of the American Association for the Study of Liver Diseases, Chicago, November 1997.